
|Articles|January 6, 2009
FDA approves Allergan’s Latisse
Irvine, Calif. - The Food and Drug Administration (FDA) has approved Latisse (bimatoprost ophthalmic solution)0.03 percent for the treatment of eyelash hypotrichosis, according to Allergan.
Advertisement
Irvine, Calif.
- The Food and Drug Administration (FDA) has approved Latisse (bimatoprost ophthalmic solution)0.03 percent for the treatment of eyelash hypotrichosis, according to Allergan.
Latisse will be the only FDA approved treatment to improve eyelash length, darkness and thickness, according to a press release.
Latisse will be available within the first quarter of 2009.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
CSU With Biochemical C1 Inhibitor Deficiency: Case Report Raises Diagnostic Questions
2
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
3
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
4
Oral Minoxidil's Steady-State Release Avoids Cardiotoxic Peaks
5











